Health ❯ Pharmaceuticals ❯ Drug Approval

FDA Regulations

Clinical Trials AstraZeneca Safety Testing Compounding Pharmacies National Priority Voucher Program Rare Disease Treatments New Drug Entities New Drug Policies MOLBREEVI BLA Biologics License Application

Corcept Investors Face Today’s Lead‑Plaintiff Deadline in Securities Case Over Relacorilant Disclosures

The case turns on whether Corcept downplayed FDA doubts about relacorilant's evidence.

Corcept Investors Face April 21 Deadline to Seek Lead Role in Securities Case Over Relacorilant

Corcept Investors Pressed to Seek Lead Role in Securities Suit After FDA Rebuff of Relacorilant

Law Firms Urge Corcept Investors To Seek Lead Role In Securities Case Before April 21

FDA Approves Vanda's Bysanti for Schizophrenia and Bipolar I in Adults

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

RFK Jr. Overhauls HHS With Deep Cuts, MAHA Push and Vaccine Policy Reversals

Savara Investors Pressed to Seek Lead Role in Securities Suit Before Nov. 7 Deadline

GLP-1 Agonists Tied to Higher Risk of Macular Degeneration and Rare Optic Neuropathy